H2N2 News and Research

RSS
Scientists explore antigenic imprinting in SARS-CoV-2

Scientists explore antigenic imprinting in SARS-CoV-2

Study determines hemagglutinin inhibition seroprevalence against swine influenza viruses circulating in Hong Kong and Guangzhou

Study determines hemagglutinin inhibition seroprevalence against swine influenza viruses circulating in Hong Kong and Guangzhou

Echinacea as a potential force against coronavirus infections

Echinacea as a potential force against coronavirus infections

Novel influenza vaccine candidate shows promise

Novel influenza vaccine candidate shows promise

Combo COVID-flu vaccine protects against current and emerging variants in animal model

Combo COVID-flu vaccine protects against current and emerging variants in animal model

Altering genetic mutation could enhance FluMist vaccine’s protective effect

Altering genetic mutation could enhance FluMist vaccine’s protective effect

PeptiDream develops novel macrocyclic peptide inhibitor for treatment of multiple influenza strains

PeptiDream develops novel macrocyclic peptide inhibitor for treatment of multiple influenza strains

1950s H2N2 avian influenza A virus still pose threat to human health

1950s H2N2 avian influenza A virus still pose threat to human health

Medicago, IDRI to present Phase I clinical results of H5N1 vaccine at World Vaccine Congress

Medicago, IDRI to present Phase I clinical results of H5N1 vaccine at World Vaccine Congress

Researchers report seroprevalence of three avian flu virus strains in pigs in southern China

Researchers report seroprevalence of three avian flu virus strains in pigs in southern China

Single dose of Medicago's vaccine could offer cross-protection against flu

Single dose of Medicago's vaccine could offer cross-protection against flu

Medicago, IDRI receive FDA approval to commence Phase 1 H5N1 vaccine trial

Medicago, IDRI receive FDA approval to commence Phase 1 H5N1 vaccine trial

Positive data from Inovio's VGX-3400X Phase I study against H5N1 influenza

Positive data from Inovio's VGX-3400X Phase I study against H5N1 influenza

External panel issues draft report saying WHO response to H1N1 lacked cohesion, clarity

External panel issues draft report saying WHO response to H1N1 lacked cohesion, clarity

Flu pandemics may return & mutating strains: Studies

Flu pandemics may return & mutating strains: Studies

Inovio commences immunization in U.S. Phase I clinical trial of SynCon H5N1 influenza DNA vaccine

Inovio commences immunization in U.S. Phase I clinical trial of SynCon H5N1 influenza DNA vaccine

Lethality of H1N1 virus has dropped from its peak of 3.7, shows new data

Lethality of H1N1 virus has dropped from its peak of 3.7, shows new data

Inovio Biomedical announces positive test results of its consensus influenza vaccines

Inovio Biomedical announces positive test results of its consensus influenza vaccines

Inovio Biomedical's proprietary DNA vaccine development platform introduced

Inovio Biomedical's proprietary DNA vaccine development platform introduced

Fast-tracked H1N1 vaccines will not compromise safety, WHO says

Fast-tracked H1N1 vaccines will not compromise safety, WHO says